Metastatic Malignant Neoplasm to the Leptomeninges Terminated Phase 1 / 2 Trials for Rituximab (DB00073)

Also known as: Leptomeningeal Metastasis / Neoplastic Meningitis / Leptomeningeal Metastases / Metastatic Malignant Neoplasm in the Leptomeninges / Leptomeningeal Disease (LMD) / Leptomeningeal Disease / Lymphomatous meningitis / Leptomeningeal Carcinomatosis / Metastatic malignant neoplasm to leptomeninges (disorder) / Lymphomatous meningitis (disorder) / Malignant meningitis (disorder) / Leptomeningeal Neoplasms / Meningeal dissemination / Metastases to meninges / Meningeal Carcinomatosis

IndicationStatusPhase
DBCOND0057483 (Metastatic Malignant Neoplasm to the Leptomeninges)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01596127Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous SystemTreatment